Nanoform Finland Oyj

Helsinki Stock Exchange NANOFH.HE

Nanoform Finland Oyj EBITDA Margin for the year ending December 31, 2023: -687.79%

Nanoform Finland Oyj EBITDA Margin is -687.79% for the year ending December 31, 2023, a -24.57% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Nanoform Finland Oyj EBITDA Margin for the year ending December 31, 2022 was -552.12%, a 36.31% change year over year.
Nanoform Finland Oyj EBITDA Margin for the year ending December 31, 2021 was -866.88%, a 66.80% change year over year.
Nanoform Finland Oyj EBITDA Margin for the year ending December 31, 2020 was -2,611.39%, a 81.52% change year over year.
Nanoform Finland Oyj EBITDA Margin for the year ending December 31, 2019 was -14,134.08%, a -1,716.92% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Helsinki Stock Exchange: NANOFH.HE

Nanoform Finland Oyj

CEO	Prof. Edward Olof Haeggstrom
IPO Date	June 4, 2020
Location	Finland
Headquarters	Cultivator II
Employees	174
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Engineering Services

Description

Nanoform Finland Oyj provides nanotechnology and drug particle engineering services for the pharmaceutical industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients. The company was founded in 2008 and is headquartered in Helsinki, Finland.

Key trends

Past 5 years